METHOD AND COMPOSITION FOR TREATING OBESITY
A method for treating obesity associated with Prader Willi Syndrome is disclosed.
1 . A method of treating Prader-Willi syndrome in a subject, the method comprising:
administering via inhalation a dry powder composition including pramlintide and a crystalline, amorphous, or crystalline composite form a compound having a formula:
2 . The method of claim 1 , wherein the administering is in a single inhalation.
3 . The method of claim 1 , wherein the administering is immediately prior to beginning a meal.
4 . The method of claim 1 , wherein the administering is prandially.
5 . The method of claim 4 , wherein the administering is at time 0.
6 . The method of claim 1 , wherein the subject is obese.
7 . The method of claim 1 , wherein the dry powder composition further includes alanine, glycine, leucine, isoleucine, norleucine, serine or a combination thereof.
8 . The method of claim 7 , wherein the aliphatic amino acid is about 0.5% to about 30% by weight.
9 . The method of claim 7 , wherein the aliphatic amino acid is L-leucine.
10 . The method of claim 1 , wherein the dry powder composition further comprises insulin.
11 . The method of claim 10 , wherein the insulin is a rapid acting insulin.
12 . The method of claim 10 , wherein the insulin comprises up to about 30% by weight.
13 . The method of claim 1 , wherein the dry powder composition further comprises a serotonin receptor agonist.
14 . The method of claim 13 , wherein the serotonin receptor agonist is a triptan.
15 . The method of claim 14 , wherein the triptan is sumatriptan, zolmitriptan, rizatriptan, naratriptan, almotriptan, eletriptan, or frovatriptan.
16 . The method of claim 1 , wherein the dry powder composition is used in combination therapy with a rapid acting insulin, fluoxetidine, or duloxetine, or combinations thereof.
17 . The method of claim 1 , wherein the pramlintide is present up to 10 mg by weight.
18 . The method of claim 1 , wherein the pramlintide is present up to 3 mg of dry powder composition for a single dose.
19 . A method of treating Prader-Willi syndrome, the method comprising:
providing to a subject a unit dose cartridge configured to be used in a dry powder inhaler a dry powder composition including pramlintide and a crystalline, amorphous, or crystalline composite form of a compound having a formula:
20 . The method of claim 19 , wherein the dry powder inhaler is reusable.